SLC5A2 and type 2 diabetes mellitus: SGLT2 inhibitors are a new class of antihyperglycaemic drugs that are prescribed mainly for type 2 diabetes patients whose blood sugar remains uncontrolled despite treatment with metformin and sulfonylurea 6.